Daniel R Sill

Detailed Reanalysis of 500 Breast Cancers With Equivocal HER2 Immunohistochemistry and Borderline ERBB2 Fluorescence In Situ Hybridization Results.

R. Jenkins, T. Mounajjed, G. Spears, 2021, American journal of clinical pathology.

Working Up Group 4 Equivocal HER2 Samples Tested by Fluorescence in Situ Hybridization in a Reference Laboratory Setting: Past, Present, and Future.

R. Jenkins, T. Mounajjed, Beiyun Chen, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

HER2 Testing for Breast Cancer in the Genomics Laboratory: A Sea Change for FISH.

J. Carter, R. Jenkins, T. Mounajjed, 2020, Archives of Pathology & Laboratory Medicine.